Sanofi announced today it entered into an agreement to acquire Origimm Biotechnology GmbH, an Austrian privately owned biotechnology company specializing in the discovery of virulent skin microbiome components and antigens from bacteria causing skin disease, such as acne. With this acquisition, Sanofi continues executing its global Play to Win strategy, pursuing growth opportunities and building an industry-leading vaccines pipeline.
- Read more about Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/sanofi-to-acquire-origimm-biotechnology-in-first-move-to-treat-acne-with-vaccine-based-immunotherapy
No comments:
Post a Comment